Gonadal Function in Adult Male Patients with Congenital Adrenal Hyperplasia by Engels, Manon et al.
 
 
Gonadal Function in Adult Male Patients with
Congenital Adrenal Hyperplasia
Engels, Manon; Gehrmann, Katharina; Falhammar, Henrik; Webb, Emma; Nordenstrom,
Anna; Sweep, Fred; Span, Paul N; van Herwaarden, Antonius Eduard; Rohayem, Julia;
Richter-Unruh, Annette; Bouvattier, Claire; Koehler, Birgit; Kortmann, Barbara B; Arlt, Wiebke;
Roeleveld, Nel; Reisch, Nicole; Stikkelbroeck, Nike; Claahsen-van der Grinten, Hedi L
DOI:
10.1530/EJE-17-0862
License:
None: All rights reserved
Document Version
Peer reviewed version
Citation for published version (Harvard):
Engels, M, Gehrmann, K, Falhammar, H, Webb, EA, Nordenstrom, A, Sweep, F, Span, PN, van Herwaarden,
AE, Rohayem, J, Richter-Unruh, A, Bouvattier, C, Koehler, B, Kortmann, BB, Arlt, W, Roeleveld, N, Reisch, N,
Stikkelbroeck, N & Claahsen-van der Grinten, HL 2018, 'Gonadal Function in Adult Male Patients with
Congenital Adrenal Hyperplasia', European Journal of Endocrinology. https://doi.org/10.1530/EJE-17-0862
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Disclaimer: this is not the definitive version of record of this article.This manuscript has been accepted for publication in European Journal of
Endocrinology, but the version presented here has not yet been copy-edited, formatted or proofed. Consequently, Bioscientifica accepts no
responsibility for any errors or omissions it may contain. The definitive version is now freely available at: http://dx.doi.org/10.1530/EJE-17-
0862, 2018
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
1 
 
Gonadal Function in Adult Male Patients with Congenital Adrenal Hyperplasia 1 
Authors: M. Engels1,2; K. Gehrmann3; H. Falhammar4,5; E.A. Webb6,7; A. Nordenström8; F.C. Sweep2; 2 
P.N. Span9; A.E. van Herwaarden2; J. Rohayem10; A. Richter-Unruh10; C. Bouvattier11; B. Köhler3; B.B. 3 
Kortmann12; W. Arlt6,7; N. Roeleveld13; N. Reisch14; N.M.M.L. Stikkelbroeck15; H.L. Claahsen - van der 4 
Grinten1 on behalf of the dsd-LIFE group#. 5 
Affiliations:  6 
1 Department of Pediatrics, Amalia Children's Hospital, Radboud university medical center, P.O. Box 7 
9101, 6500HB Nijmegen, the Netherlands  8 
2 Department of Laboratory Medicine, Radboud Institute for Molecular Life Sciences (RIMLS), 9 
Radboud university medical center, P.O. Box 9101, 6500HB Nijmegen, the Netherlands  10 
3 Klinik für Pädiatrie m.S. Endokrinologie und Diabetologie, Charité – Universitätsmedizin Berlin, 11 
corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of 12 
Health, Augustenburger Platz 1, 13353 Berlin, Germany 13 
4 Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, 14 
Sweden 15 
5 Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden 16 
6 Institute of Metabolism and Systems Research (IMSR), University of Birmingham, Birmingham, 17 
United Kingdom 18 
7Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, 19 
United Kingdom 20 
8 Department of women’s and children’s health, Division of Pediatric Endocrinology, Karolinska 21 
Institutet, Karolinska University Hospital, Stockholm, Sweden 22 
2 
 
9 Department of Radiation Oncology, Radiotherapy & OncoImmunology laboratory, RIMLS, Radboud 23 
university medical center, Nijmegen, the Netherlands  24 
10 Centre of Reproductive Medicine and Andrology, Clinical Andrology, University Hospital Münster, 25 
Albert Schweitzer Campus 1; Building D 11, 48129 Münster, Germany 26 
11 Endocrinologie pédiatrique, Centre de référence des maladies rares du développement sexuel , 27 
Hôpital Bicêtre, , Université Paris-Sud, 78 rue du General Leclerc, 94270 Le Kremlin-Bicêtre, France  28 
12 Department of Pediatric Urology, Radboud university medical center, P.O. Box 9101, 6500HB 29 
Nijmegen, the Netherlands  30 
13 Department for Health Evidence, Radboud university medical center, P.O. Box 9101, 6500HB 31 
Nijmegen, the Netherlands  32 
14 Medizinische Klinik IV, Klinikum der Universität München, München, Germany 33 
15 Department of Internal Medicine, Radboud university medical center, P.O. Box 9101, 6500HB 34 
Nijmegen, the Netherlands  35 
# Members of dsd-LIFE group are: Birgit Kohler, Berlin; Peggy Cohen-Kettenis and Annelou de Vries, 36 
Amsterdam; Wiebke Arlt, Birmingham; Claudia Wiesemann, Gottingen; Jolanta Slowikowska-Hilczer, 37 
Lodz; Aude Brac de la Perriere, Lyon; Charles Sultan and Francoise Paris, Montpellier; Claire 38 
Bouvattier, Paris; Ute Thyen, Lubeck; Nicole Reisch, Munich; Annette Richter-Unruh, Munster; Hedi 39 
Claahsen-van der Grinten, Nijmegen; Anna Nordenstrom, Stockholm; Catherine Pienkowski, 40 
Toulouse; and Maria Szarras-Czapnik, Warsaw 41 
Corresponding author and person to whom reprint requests should be addressed: 42 
Hedi Claahsen-van der Grinten, MD, PhD 43 
Department of Pediatrics  44 
3 
 
Radboud university medical center (804) 45 
P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.  46 
Phone: 0031-24-3614430 47 
Fax: 0031-24-3616428 48 
E-mail: Hedi.Claahsen@radboudumc.nl 49 
Short title: Gonadal function in adult men with CAH 50 
Keywords: congenital adrenal hyperplasia; gonadal function; fertility; testicular adrenal rest tumor; 51 
hypogonadism 52 
Word count: 3593 3779  53 
  54 
4 
 
Abstract 55 
Context: Current knowledge on gonadal function in Congenital Adrenal Hyperplasia (CAH) is mostly 56 
limited to single center/country studies enrolling small patient numbers. Overall data indicate that 57 
gonadal function can be compromised in men with CAH. Gonadal function can be compromised in 58 
male patients with congenital adrenal hyperplasia (CAH), however previous studies have been 59 
limited to reports from a single center/country or small patient numbers. 60 
Objective: To determine gonadal function in men with CAH within the European “dsd-LIFE” cohort. 61 
Design: Cross-sectional clinical outcome study, including retrospective data from medical records. 62 
Methods: Fourteen academic hospitals included 121 men with CAH aged 16-68 years. Main outcome 63 
measures were serum hormone concentrations, semen parameters, and imaging data of the testes. 64 
Results: At the time of assessment, 19/83 14/69 patients had a serum testosterone concentration 65 
level below the reference range; 8 7 of those were hypogonadotropic, 10 6 normogonadotropic, and 66 
1 hypergonadotropic. In contrast, in the presence of among the patients with normal serum 67 
testosterone (64/83 55/69), 5 4 patients were hypogonadotropic, 50 44 normogonadotropic, and 9 7 68 
hypergonadotropic. The association of decreased testosterone with reduced gonadotropin 69 
concentrations (Odds Ratio (OR)=8.0 [2.2-29.6] 12.8 [2.9-57.3]) was weaker than the association 70 
between serum androstenedione/testosterone ratio ≥ 1 and reduced gonadotropin concentrations 71 
(OR=16.8 [2.0-142.5] 39.3 [2.1-732.4]). Evaluation of sperm quality revealed decreased Decreased 72 
sperm concentrations (15/39), decreased motility (13/37), and abnormal morphology (4/28) were 73 
also observed. Testicular adrenal rest tumor (TART)s were present in 39/80 patients, with a higher 74 
prevalence in patients with the most severe genotype (14/18), and in patients with increased current 75 
17-hydroxyprogesterone (12/18 20/35) or androstenedione (16/26 12/18) serum concentrations. 76 
Forty-three children were fathered by 26/113 patients. 77 
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 Conclusions: Men with CAH have a high risk of developing hypothalamic-pituitary-gonadal 78 
disturbances and spermatogenic abnormalities. Regular assessment of endocrine gonadal function 79 
and of imaging for TART development by imaging are recommended, in addition to measures for 80 
fertility protection.   81 
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Introduction 82 
Congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder resulting in impaired 83 
adrenocortical steroid synthesis by several enzyme deficiencies. The most common form (>95%) is 84 
21-hydroxylase deficiency (21OHD) with an incidence of 1:15 000, leading to glucocorticoid and often 85 
also mineralocorticoid deficiency in combination with androgen excess ies 1, 2. 86 
Reported fertility and fecundity in men with CAH on routine steroid replacement therapy range from 87 
normal to severely impaired. Fertility can be compromised due to primary (hypergonadotropic) 88 
hypogonadism or central (hypogonadotropic) hypogonadism 3-11. In addition, reduced fertility and 89 
fecundity rates problems in CAH can be caused by psychosexual factors 4. One of the commonest 90 
complications in men with CAH is the presence of Testicular Adrenal Rest Tumor (TART)s, which can 91 
cause disturbances of gonadal function, including mechanical obstruction of the seminiferous 92 
tubules. The reported prevalence of TART ranges between 12.5% and 94% of the populations 93 
studied. Central or secondary hypogonadism is defined as decreased testosterone concentrations in 94 
combination with either low or low-normal LH or FSH concentrations. In patients men with CAH, 95 
secondary hypogonadism is most likely to be caused by the suppressive effect of elevated adrenal 96 
androgens (that are aromatized to estrogens) on the hypothalamic-pituitary-gonadal (HPG)-axis 6. 97 
Differentiation between gonadal and adrenal testosterone is difficult, complicating the diagnosis of 98 
hypogonadism in patients men with CAH. One of the commonest complications in men with CAH is 99 
the presence of Testicular Adrenal Rest Tumor (TART)s, which can cause disturbances of gonadal 100 
function, including mechanical obstruction of the seminiferous tubules. The reported prevalence of 101 
TARTs ranges between 12.5% and 94% in the populations studied 4-10, 12-22. 102 
 Until now, the data on fertility outcome in men with CAH are scarce. Available data are 3-11 and often 103 
derived from studies with patients from a single center or country. Our aim was to study gonadal 104 
function in a large European multi-center cohort of male patients with CAH by evaluating hormone 105 
concentrations, semen parameters, and TART frequency. 106 
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Subjects and Methods 107 
Subjects 108 
dsd-LIFE is a cross-sectional clinical outcome study of individuals with disorders/differences of sex 109 
development (DSD). Fourteen study centers in 6 European countries (France (n=4), Germany (n=4), 110 
United Kingdom (n=1), Poland (n=2), Sweden (n=1), and the Netherlands (n=2)) included former and 111 
current patients as participants from February 2014 - September 2015. In addition to DSD 112 
participants, 121 male participants with CAH (46XY karyotype) aged 16-68 years were recruited as 113 
they may face similar clinical challenges as DSD patients, including sex hormone imbalances and 114 
fertility problems, although male patients with CAH do not fit into the classification of DSD. Written 115 
informed consent was obtained from all participants and/or their parents, with assent of minors. 116 
Ethical approvals were obtained as appropriate for each country, e.g. Ethics Commission of the 117 
Charité Universitätsmedizin; reference number EA2/069/13. For. The theoretical and methodological 118 
framework of the dsd-LIFE study have been published in detail elsewhere see Röhle 2017 et al. 23. 119 
Patients were investigated in their local treatment center. Cross-sectional data were obtained for 120 
serum hormone concentrations, semen parameters and testicular imaging. The genotype of patients 121 
with 21OHD was classified into genotype groups null, A, B, and C 24. Patients were also classified into 122 
salt-wasting (SW), simple virilizing (SV) or non-classical (NC) based on their main symptoms and time 123 
of diagnosis General patient characteristics and clinical parameters included: country of inclusion, 124 
age, age at diagnosis, CAH genotype and phenotype, socioeconomic status, and obesity, as well as 125 
height, weight, and BMI throughout the years (at diagnosis, 9 months old, 6 years old, Tanner stage 126 
2, 16 years old, and current age). Patients’ educational levels was established according to the EU 127 
classification. We combined the standardized ES-ISCED (international standard classification of 128 
education) scale to Low (ES-ISCED I = less than lower secondary and ES-ISCED II = lower secondary); 129 
medium (ES-ISCED IIIb = lower tier upper secondary; ES-ISCED IIIA = upper tier upper secondary; ES-130 
ISCED IV = advanced vocational, sub-degree) and high (ES-ISCED V1 = lower tertiary education, BA 131 
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level; ES-ISCED V2 = higher tertiary education, >=MA level). Data was collected during medical 132 
examination at study inclusion (cross-sectional) and retrieved from medical records (retrospective 133 
data).  134 
Hormonal analysis 135 
Blood samples were taken during day time, but mostly in the morning, before intake of the 136 
glucocorticoid medication 23. Total testosterone, SHBG, LH, FSH, inhibin B, AMH, androstenedione, 137 
17-hydroxyprogesterone (17OHP) concentrations, and renin/plasma renin activity were measured in 138 
the local hospital laboratory and compared to local references. Values are reported in SI or 139 
international units and reported as “below reference range”, “within reference range”, “above 140 
reference range up to twice the upper limit", and "more than twice the upper limit of the reference 141 
range”. To increase the number of patients per category, we combined the latter 2 categories into 142 
the category "above reference range". 143 
The serum androstenedione/testosterone ratio (AD/T) was calculated and divided into normal (<0.5; 144 
interpreted as testosterone mainly of testicular origin), ≥0.5 and <1 (significant fraction of 145 
testosterone is of adrenal origin), and ≥1 (testosterone mainly of adrenal origin ) as suggested by 146 
others 25.  147 
Three patients were excluded from part of the analyses as they received testosterone substitution, 148 
which directly affects testosterone and gonadotropin concentrations. Two of these patients had data 149 
on TART available; these are described in the results section, but were otherwise excluded from 150 
further analyses. 151 
Semen analysis 152 
Semen analysis was performed by the local hospital laboratory and interpreted in accordance with 153 
the 2010 World Health Organization criteria 26, including sperm concentration (lower reference limit 154 
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(LRL): 15x106/mL) , motility (LRL: 40%), morphology (LRL: 4%), vitality (LRL: 58%), and volume (LRL: 155 
1.5 mL).  156 
Imaging of testes 157 
At the study visit, 68 patients (56.2%) underwent testicular ultrasound. The presence of TART at the 158 
age of 16 years was also reported retrospectively (in 30/68 patients with cross-sectional TART data). 159 
In addition, retrospective data were available for 12 participants based on ultrasound findings or MRI 160 
(n=11) and on histological findings (n=1).  161 
Paternity 162 
Data about paternity and relationships were collected from the dsd-LIFE questionnaires 23.  163 
Medication and estimation of metabolic control in the past 164 
Patients used different formulations of glucocorticoids, including hydrocortisone, prednisone, 165 
prednisolone, and dexamethasone. Furthermore, we converted all All glucocorticoid preparations 166 
were converted to hydrocortisone equivalents for comparison, using the following factors for the 167 
glucocorticoid equivalent dose: 1 (hydrocortisone), 4 (prednisone or prednisolone), 30 168 
(dexamethasone), and 15 (fludrocortisone)27. We also calculated mineralocorticoid equivalent dose 169 
using the following factors: 1 (hydrocortisone), 0.8 (prednisone or prednisolone), 0 (dexamethasone), 170 
and 200 (fludrocortisone)27. In addition to the serum 17OHP concentrations presented in the section 171 
hormonal analysis, we also assessed metabolic control by a subjective rating, of metabolic control of 172 
the local examining physician at 5 different time points: at diagnosis, at the age of 9 months, at 173 
Tanner stage 2, at age 16 years and at study inclusion, using the following scores: "poor", 174 
"moderate", "good", "excellent" or "unknown".  175 
Statistical Analysis 176 
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SPSS Statistics 22 (SPSS Inc., Chicago, IL, USA) was used for all analyses. Descriptive analyses were 177 
performed for all variables. Depending on normality, mean and 95% confidence intervals (95%CI) or 178 
median and interquartile ranges (IQR) were calculated. We compared patients with values below or 179 
above reference range to patients with normal values (within the reference range). Odds ratios (OR) 180 
with 95%CI were calculated if at least 3 cases were present in both subgroups. If any cell count in the 181 
contingency table was zero, OR and 95%CI were calculated manually by using a continuity correction 182 
(+0.5 in each cell).  183 
Missing data were evaluated for each variable and the total number of participants in a particular 184 
analysis was reported exactly. Analysis of the variables was only performed only if when the number 185 
of participants was ≥ at least 25% of the total cohort of male patients with CAH.  186 
Three patients were excluded from part of the analyses as they received testosterone substitution, 187 
which directly affects testosterone and gonadotropin concentrations. Two of these patients had data 188 
on TART available; these are described in the results section, but were otherwise excluded from 189 
further analyses. Furthermore, we excluded 22 patients with missing genotype information and 2 190 
patients with 11β-hydroxylase deficiency from all comparative analyses.   191 
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Results 192 
General characteristics of the male CAH cohort 193 
A total of 121 male patients were included in the CAH cohort in the dsd-LIFE study. General 194 
characteristics are shown in Table 1. The median age of the study population was 28 years (IQR: 18.5-195 
37.5, range 16-68). Mean height was 170.7 (95%CI: 169.3-172.0) cm and median BMI was 25.6 (IQR: 196 
22.0-29.2) kg/m2 (data available for 119 patients). Nearly Almost all patients had 21OHD (119/121), 197 
of which and 97 were confirmed by molecular genetic analysis and 22 were based on phenotype 198 
alone. The remaining 2 patients had 11β-hydroxylase deficiency. Among the 97 patients with 199 
genetically confirmed 21OHD, Genotype groups null, A, B, and C contained 19.8% 24.7% were 200 
classified as genotype null, 30.6% 38.1% as genotype A, 27.3% 34.0% as genotype B, and 2.5% 3.1% 201 
as genotype C. of the 97 patients with genotyping results. The majority of patients (62.0%) were 202 
classified as having the SW form of CAH, 31.4% had the SV form and 4.1% had the NC form. 203 
Glucocorticoids were used by 116 (95.9%) patients, most commonly hydrocortisone, followed by 204 
prednisone or prednisolone, and dexamethasone. Fludrocortisone was used by 86 patients (71.1%). 205 
The patients' education was intermediate or high in 54.5%, and 22.3% of the participants, 206 
respectively. Furthermore, 54.6% of the patients were in a relationship at the time of study.  207 
We analyzed all variables mentioned in the method section, but we only present in detail the data 208 
that differed between the analyzed groups (no overlap in the confidence intervals). In the following 209 
sections we will present data regarding hormone concentrations, semen analysis and TART. 210 
Hormone concentrations  211 
Univariate descriptive analyses of hormone concentrations were performed. The proportion of 212 
patients with normal, decreased or increased serum testosterone, LH, FSH, inhibin B, AMH, and SHBG 213 
concentrations is illustrated in Figure 1A. Hormone concentrations were below the reference range 214 
in 19/97 (19.6%: testosterone), 8/43 (18.6%: inhibin B), 12/90 (13.3%: LH), 9/90 (10.0%: FSH), and 215 
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1/69 (1.4%: SHBG) of the participants. SHBG concentrations were above the reference range in 14.5% 216 
(10/69).  217 
Table 2 shows compares testosterone and gonadotropin concentrations in all patients with data on T, 218 
LH, and, FSH available. that in p Seven patients (50%) with decreased testosterone concentrations 219 
(19/83), 8 (42.1%) had decreased gonadotropins, while 10 6 (52.6 42.9%) had normal LH and FSH 220 
concentrations, and 1 (5.3 7.1%) patient had gonadotropin concentrations above reference range. 221 
Normal testosterone concentrations were found in 64/83 55/69 (77.1 79.7%) patients, 50 44 (78.1 222 
80.0%) of whom had normal gonadotropin concentrations, whereas 9 7 (14.1 12.7%) had increased, 223 
and 5 4 (7.38%) had decreased concentrations. Decreased testosterone concentrations were clearly 224 
associated with decreased LH and/or decreased FSH concentrations (OR 8.0 12.8, 95%CI: 2.9 - 2 - 225 
29.6 57.3).  226 
A serum An AD/T ratio was calculated in 49 patients, 22 of whom (44.9%) had an AD/T ratio ≥1. Ten 227 
patients (45.5%) with an AD/T ≥1 had decreased gonadotropins, while 11 (50.0%) patients had 228 
normal gonadotropins and only 1 (4.5%) patient had increased gonadotropins. Normal AD/T ratios 229 
were found in 27/49 (55.1%) patients, 21 of whom had normal gonadotropin concentrations (77.8%), 230 
5 had increased concentrations, but none had decreased gonadotropin concentrations. was found in 231 
7/8 patients (87.5%) with decreased testosterone and gonadotropins, while 4/5 patients (80.0%) 232 
with normal testosterone and decreased gonadotropins had an AD/T ratio ≥1. Moreover, 5/10 233 
patients (50.0%) with decreased testosterone and normal gonadotropins had an AD/T ratio ≥1, 234 
whereas this was seen in only 11/50 patients (22.0%) with normal testosterone and gonadotropins. 235 
An AD/T ratio ≥1 was strongly associated with decreased LH and/or decreased FSH concentrations 236 
(OR 16.8 39.3, 95%CI: 2.10 - 142.5 732.4).  237 
Semen analysis  238 
Semen analysis was performed in approximately one third of the patients (Figure 1B). Normal values 239 
for all known (at least 3 out of 5) semen parameters (normozoospermia) were seen in 11/39 patients 240 
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in which semen analysis was performed. Sperm concentration, motility, and volume were below the 241 
normal ranges in 38.5% (15/39), 35.1% (13/37), and 25.6% (10/39) of the patients, respectively, while 242 
morphology and vitality were both impaired in 14.3% (4/28 and 2/14) of the patients. Five of 8 243 
patients (62.5%) with decreased testosterone and gonadotropin concentrations underwent semen 244 
analysis, with 4 (80.0%) of them showing abnormal semen parameters (Table 3). In only 2/10 245 
patients with decreased testosterone, but normal gonadotropin concentrations, semen analysis was 246 
performed and both had decreased sperm concentrations (7.0 and 10.0 x106/mL). No statistically 247 
significant associations were found (data not shown).  248 
Testicular adrenal rest tumors  249 
TARTs were visualized by ultrasound or MRI at cross-sectional investigation in 28/68 patients. For 1 250 
patient, the diagnosis was based on retrospective histology data. Furthermore, retrospective imaging 251 
data were available for 11 men: TARTs were present in 10 of these individuals. So, in In the total 252 
population screened, TARTs were present in 39/80 patients (48.8%) of which 34 were bilateral TARTs 253 
(87.2%). Documented retrospective TARTs at age 16 years were reported in 16/30 patients (53.3%), 254 
all of which were bilateral. In only 2/16 patients (12.5%) with TART reported to be present at age 16, 255 
TART was no longer observed during the cross-sectional investigation: one patient was misdiagnosed 256 
with TART as it appeared to be a varicocele, and in the other patient TART (size 2 mm) disappeared 257 
after treatment with prednisone. This patient was still considered as a TART patient with TART in all 258 
analyses. 259 
Comparison of patients with and without TART 260 
Table 4 shows associations of TART with various variables in the 78 68 patients with gonadal imaging 261 
data (12 patients were excluded due to testosterone substitution, 11β-hydroxylase deficiency or 262 
unconfirmed 21-hydroxylase deficiency), comprising 37 33 patients with and 41 35 without TARTs. 263 
Genotype was clearly associated with the presence of TART: The null genotype group had the highest 264 
prevalence of TART (14/18: 77.8%), while the prevalence was 10/27 (37.0%) for genotype group A, 265 
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and 7/21 (33.3%) for genotype group B. The odds of having TART in the null genotype group was 6.0 266 
[1.5-23.1] and 7.0 [1.7-29.4] times higher compared to the genotype groups A and B, respectively. 267 
TARTs were also present in both men in the genotype C group, and also in 1 CYP11B1-deficient 268 
patient (the other CYP11B1 patient did not undergo assessment for TART). The OR of having TART 269 
when having an a serum androstenedione level concentration above the upper limit of normal at the 270 
time of the cross-sectional investigation was 3.6 3 [1.0 - 11.2 12.7]. Similar associations were found 271 
for serum 17OHP at the cross-sectional investigation, with an OR of 6.4 28.0 [1.7 3.1 - 24.7 252.5] for 272 
having TART when 17OHP concentrations were more than twice the upper level of the reference 273 
range, and an OR of 4 18.7 [1.3 2.2 - 158.1 16.5] when these concentrations were above the 274 
reference range compared to concentrations within the reference range.  275 
Paternity  276 
Data on paternity were available for 113 of the 121 patients, 26 (23.0%) of whom (age range 26-68 277 
years) had fathered a total of 43 children. Three couples had used assisted reproductive techniques 278 
(ART) resulting in 4/43 children. One of the men who had used ART had decreased testosterone 279 
concentrations, while another had increased FSH, decreased sperm concentration, and TART. No 280 
information was available about the third patient who had used ART. One man with impaired semen 281 
motility, increased FSH concentrations, and TART had adopted a child.  282 
Discussion 283 
This unique and relatively large European multicenter study shows that gonadal dysfunction is a 284 
common complication in male patients with CAH. Approximately half of the patients were affected 285 
by endocrine disturbances of the HPG axis at an adult age and TARTs were present in approximately 286 
half of the patients as well. 287 
The difficulty in diagnosing hypogonadism in men with CAH is related to the fact that testosterone 288 
measured in serum is a mixture of testosterone of gonadal and adrenal origin 25, 28. Circulating 289 
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testosterone in male patients with well-controlled CAH is predominantly derived from testicular 290 
production, but when there is poor hormonal control, a relevant contribution arises from adrenal 291 
steroidogenesis. Until now, no method is able to discriminate between testosterone derived from 292 
the testes or the adrenal gland. Therefore, it has been suggested to use the serum AD/T ratio in male 293 
patients with CAH, as this precursor steroid is elevated in serum when serum androgens are 294 
predominantly of adrenal origin 25. Our data point toward an association confirmed a stronger 295 
association between an AD/T ratio ≥1 (testosterone mainly of adrenal origin) and decreased LH 296 
and/or decreased FSH concentrations compared to testosterone concentrations alone, suggesting 297 
that adrenal androgens in men with CAH contribute to the suppression of gonadotropins. In 298 
approximately half of the patients, either aberrant testosterone or AD/T ratios, or aberrant 299 
gonadotropin concentrations, or a combination of both were found. In previous studies, the reported 300 
prevalence of endocrine HPG axis disturbances ranged from 20% to 52% 5-7, 9, 10. However, only 1 301 
other report study provided had information on testosterone and gonadotropin concentrations in 302 
each patient, and also indicated endocrine disturbances hypogonadism in approximately half of the 303 
patients 6. We recommend to including include the evaluation of the AD/T ratio in the regular follow-304 
up androstenedione measurements in the gonadal evaluation of male patients with CAH to calculate 305 
the AD/T ratio, and interpret this ratio in combination with gonadotropin concentrations in order to 306 
detect a disturbance of the HPG axis. Our study did does not include data information on 11-307 
oxygenated androgens, that are generated through conversion of androstenedione, and are reported 308 
to be elevated concentrations are found in patients with CAH 29, 30. Recent studies indicate that 11-309 
oxygenated androgens are almost entirely derived from the 11beta-hydroxylation of 310 
androstenedione in the adrenal, and as they are potent androgens they can contribute to 311 
suppression of the HPG axis31. However, their exact role in the evaluation of However, their 312 
associations with hormonal control and gonadal function in men with CAH has to be established in 313 
further studies. Serum AMH and inhibin B are also used as markers for male fertility 32. However, 314 
literature already showed it has been demonstrated that serum AMH concentrations do not 315 
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correlate with sperm concentration and other male fertility parameters 33. Serum inhibin B, a marker 316 
of Sertoli cell function, is known to correlate with spermatogenesis in healthy men 34 and was 317 
decreased in 18.3% 18.6% of our cohort. Semen quality, assessed in one third of the study cohort, 318 
was reduced in 40% of the men. Except for the study of Urban et al. 3, all other studies on fertility in 319 
male patients with CAH showed decreased sperm concentrations ranging from 47.8% to 66% 4-7, 9, 10. 320 
More strikingly, in all studies only half of the participants participated in semen analysis. Taken 321 
together, these data indicate the need for Therefore, increased awareness on fertility status in 322 
patients with CAH, and to start is needed. We recommend performing semen analysis and gonadal 323 
function biomarkers assessment as early as possible in from adolescence on, in order to detect 324 
disturbances early and allow semen preservation to be able to preserve semen for later fertility 325 
purposes.  326 
Data from our cohort indicate, in agreement with previous studies The prevalence of TART in the 327 
present patient cohort was 48.8%, confirming previous reports that TART is a common complication 328 
in male patients with CAH 4-10, 12-22, that TART is a common complication in males with CAH (with a 329 
prevalence of 48.8%) and can have onset as early as in adolescence. In fact, Strikingly, 14 patients 330 
with TART at the time of the dsd-LIFE study already had TART at the age of 16 years. TARTs 331 
disappeared on at 16 years were no longer detectable following treatment with prednisone in only 1 332 
patient, thus indicating. This could indicate that complete regression of TART might only be achieved 333 
in a small proportion of the patients. Hence, prevention of the development of TART should be 334 
pursued, by optimizing treatment strategies already in childhood. Current standard of care does not 335 
include imaging of testes, however we recommend incorporating testicular ultrasound in routine 336 
clinical practice.  337 
In contrast to previous studies, several studies did not find an association between CAH severity and 338 
TART 4, 9, 10, we observed an association between the CYP21A2 genotype and the presence of TARTs, 339 
with the prevalence of this complication being was highest in men with the null CYP21A2 genotype. 340 
17 
 
This likely confirms supports the current perception that TARTs are more frequently observed in 341 
patients with a more severe form of CAH, as these patients are exposed to higher concentrations of 342 
ACTH, already in utero, which is thought to be a possible causative factor for TART development 6, 7, 15, 343 
22. However, a clinically relevant finding in this study is that TARTs occurs even in less severe forms of 344 
21OHD. In fact, in . In our study, 2 patients in genotype group C with NC CAH (both compound 345 
heterozygous for deletion and P30L mutation) had TARTs.  In our current dataset, we could not find 346 
an association between genotype and semen quality or genotype and hypogonadism. Both patients 347 
were compound heterozygous (deletion + P30L mutation). Only 1 patient in our cohort had the 348 
typical NC mutation, i.e. the V281 mutation (V281/I2Splice). No TARTs were detected in this patient.  349 
In our study, we We found an association between increased 17OHP concentrations at cross-350 
sectional data assessment and the presence of TART. Although a single 17OHP measurement may 351 
not be representative of overall metabolic control, these results could be interpreted as a possible 352 
indicator of the patient´s metabolic control in the recent past. Therefore, our results seem to be in 353 
accordance with literature reporting higher TART prevalence in patients with poor hormonal control 354 
compared to patients with adequate hormonal control 5, 7, 13, 35-38. The association between increased 355 
androstenedione concentrations at cross-sectional data assessment and the presence of TARTs adds 356 
evidence to this pathophysiologic concept, even if the AD/T ratios were not clearly associated with 357 
TART within this subgroup of patients. Primary gonadal dysfunction may be suggested by raised FSH 358 
concentrations. In our dataset, 10 patients (11.1%) had elevated FSH concentrations. Seven of these 359 
patients had data on the presence of TART, and 4 had evidence of TART. King et al. found that 360 
testicular failure was a consequence of TART in the majority of cases 10. However, our data are 361 
limited and do not allow firm conclusions concerning this issue. We cannot confirm the findings of 362 
King as we have only very limited data available. 363 
Despite this being the first international multicenter study describing gonadal function in male 364 
patients with CAH, the study also has some limitations. All centers included in this consortium are 365 
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tertiary care centers, therefore it is possible that the patient groups were selected and that the 366 
patients included were more severely affected. Furthermore, serum hormone concentrations were 367 
not measured centrally, but in various centers with a range of different assays. Accounting for this 368 
fact, only range variables were used in the data analyses. The median BMI in our patient cohort was 369 
25.6 kg/m2 (range 22.0-29.2), which is slightly overweight. It has been demonstrated that excess of 370 
total and abdominal body fat could represent one cause of fertility impairment in men with CAH 25. 371 
Serum total testosterone can be decreased in patients with obesity, as a result of the decreased 372 
serum concentration of SHBG. In case of increased serum SHBG (induced by hepatitis, 373 
hyperthyroidism, or a genetic variant), total testosterone may be increased. Ideally, free testosterone 374 
should be measured in these cases, but this requires complex equilibrium dialysis 39. Free 375 
testosterone can also be calculated from the level of total testosterone, SHBG, and albumin 376 
concentrations, but it is crucial that the results of such calculations are compared with the normal 377 
range of each separate laboratory. Such data were not available. We are aware that assessment of 378 
fertility by paternity numbers in our study was is incomplete, as many other factors, of which 379 
including female fertility, are important as well. However, these data were not available. 380 
Furthermore, participation in the medical examination was not obligatory compulsory for study 381 
inclusion. This may have led to even more selection, especially concerning the ultrasound 382 
examination and semen analysis. It is likely that only the very motivated patients and the more 383 
severely affected patients consented to these additional examinations. Due to the resulting low 384 
numbers of available data, multivariable logistic regression analyses were not possible. 385 
In summary, impaired gonadal function is common in adult men with CAH. This is indicated by the 386 
presence of TART and/or hypogonadotropic or hypergonadotropic hypogonadism. The risk of TART is 387 
highest in men with the most severe forms of enzyme deficiencies underlying CAH. Our data suggest 388 
that an An association with poor previous hormonal control is likely but has to be confirmed requires 389 
confirmation by further prospective studies. Determination of the serum AD/T ratio, in addition to 390 
serum concentrations of testosterone, androstenedione, LH, and FSH may help to differentiate 391 
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between testicular and adrenal androgens in male patients with CAH and to estimate the degree 392 
diagnose of gonadal dysfunction. Routinely performed semen analysis, measurement of serum 393 
inhibin B, and testicular ultrasound investigation already in adolescence are recommended to detect 394 
upcoming reproductive problems and to allow for fertility preserving measures, such as sperm 395 
banking.  396 
  397 
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Figure legends 540 
Figure 1: Hormone concentrations (A) and semen quality (B) in male patients with congenital 541 
adrenal hyperplasia to assess gonadal function. Stacked bars represent percentage of patients 542 
within a category. Numbers in the bars represent the specific number of patients within a category, 543 
while the total number of patients included in this analysis is stated underneath the x-axis. A) 544 
Hormone concentrations of each patient were measured in the local hospital and compared to the 545 
hospitals standard reference ranges. B) Semen analysis was performed and scored according to 546 
World Health Organization 2010 criteria 26: sperm concentration, motility, morphology, and vitality, 547 
and semen volume were assessed. Abbreviations: AMH, anti-Müllerian hormone; INHB, inhibin B; N, 548 
number of patients; T, testosterone.  549 
